Coronavirus STORY (Serum Testing of Representative Youngsters)
- Funded by Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)
- Total publications:1 publications
Grant number: MC_PC_19081
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$708,887.59Funder
Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)Principal Investigator
Prof. Matthew SnapeResearch Location
United KingdomLead Research Institution
University of OxfordResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Adolescent (13 years to 17 years)Children (1 year to 12 years)Infants (1 month to 1 year)Newborns (birth to 1 month)
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
This COVID-19 Rapid Response award is jointly funded (50:50) between the Medical Research Council and the National Institute for Health Research. The figure displayed is the total award amount of the two funders combined, with each partner contributing equally towards the project. This COVID-19 paediatric sero-epidemiology study will adapt an existing national researchnetwork and ethically-approved NIHR-funded study to collect sufficient childhood andteenage serum samples for near real-time monitoring of increases in paediatric COVID-19sero-positivity rates across the UK in 2020.The importance of sero-epidemiological monitoring is emphasised in the Public HealthEngland (PHE) pandemic influenza protocol, currently being adapted in response to theCOVID-19 threat. This requires the monthly collection of 1000 serum samples, including100 per month in each of the 0-4, 5-9, 10-14 and 15-19 year old age-groups. This isessential to understanding the rates of symptomatic and asymptomatic infection inchildren, a population that are the predominant transmitters of most respiratory viruses.This information is in turn crucial to understanding the severity of COVID-19 disease inchildren, as well as modelling the spread of this virus through the community and planningan effective public health response.The challenge of obtaining blood samples from representative cohorts of children (ratherthan residual sera from sampling for clinical purposes) had already led to the OxfordVaccine Group (OVG), PHE and seven regional partners throughout England establishingthe 'What's the STORY (Serum Testing of Representative Youngsters)' network toevaluate antibody levels against vaccine-preventable diseases. This study hascommenced, and with additional funding would be expanded to collect 3200 samplesthroughout 2020, including collection of individual level information on recent respiratoryillnesses and relevant medical history. Further extension would be possible if needed withappropriate resourcing. This study will form a rapid, responsive and crucial component ofthe UK response to this emerging global threat.
Publicationslinked via Europe PMC
Last Updated:5 days ago
View all publications at Europe PMC